Skip to main content
PFE
NYSE Life Sciences

Pfizer Pays $330M Upfront for Starna's In Vivo CAR-T Autoimmune Pipeline

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$28.28
Mkt Cap
$162.275B
52W Low
$23.62
52W High
$31.44
52W Position info
20% above low
Off High info
10% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PFE sits 20% above its 52-week low of $23.62.

Summary

Pfizer is licensing three early-stage autoimmune programs from Starna Therapeutics, paying $330 million upfront with up to $2.3 billion more tied to development and commercial milestones, plus royalties on sales. The deal gives Pfizer exclusive rights outside Greater China to the three in vivo CAR-T programs, with an option to add that region later, plus options to license compounds from a separate research collaboration and access to Starna's proprietary in vivo CAR-T technology for inflammation, immunology and oncology applications. The three initial programs remain at the pre-investigational new drug application stage; Pfizer leads clinical development outside Greater China and manufactures finished drug products for initial clinical trials at its U.S. facilities. The assets are in vivo CAR-T therapies, an emerging approach Pfizer's inflammation chief Michael Vincent called promising for patients poorly served by current options. The upfront is small against Pfizer's scale, so the near-term financial impact is modest; the real question is whether these early programs survive clinical development. This adds to a busy stretch of pipeline news, following the October tilrekimig Phase 2 win and the Metsera GLP-1 acquisition.

Updated with a Benzinga report · What changed

Updates

  1. · Benzinga — Pfizer's Starna deal gives it exclusive rights outside Greater China to three in vivo CAR-T programs, plus options to license compounds from a separate research collaboration.

    • Pfizer leads clinical development outside Greater China; manufactures finished drug products for initial clinical trials at its U.S. facilities
    • The three initial programs remain at the pre-investigational new drug application stage
    • Pfizer gains access to Starna's proprietary in vivo CAR-T technology for inflammation, immunology and oncology applications

At the time of this announcement, PFE was trading at $28.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $162.3B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.12
Real-time Price: $28.03 info
Change: -$1.09 (-4%) info
Market Cap: $159.938B info
PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $28.03 info
Change: -$0.8225 (-3%) info
Market Cap: $159.938B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $28.03 info
Change: -$1.42 (-5%) info
Market Cap: $159.938B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $28.03 info
Change: -$2.63 (-9%) info
Market Cap: $159.938B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $28.03 info
Change: -$2.59 (-8%) info
Market Cap: $159.938B info